Eli Lilly has won FDA approval for Foundayo (orforglipron), a once-daily GLP-1 pill for chronic weight management in adults with obesity, or overweight with weight-related medical problems. The approval adds a major new competitor to Novo Nordisk’s oral Wegovy, but the more important question may be what this changes for patients in daily life.
Foundayo can be taken any time of day, with or without food or water. That gives Lilly a practical advantage in the oral GLP-1 market and may make treatment easier to follow over time. Robert Gabbay, MD, PhD, described the approval as the end of the oral GLP-1 “fasting era,” and Michael Albert, MD, said that benefit to real-world adherence may be bigger than it sounds.
Lilly is also pairing convenience with a clear access strategy. The company says Foundayo will be available through LillyDirect immediately, with shipping beginning April 6, followed by broader availability through retail pharmacies and telehealth providers. Pricing starts at $25 per month for eligible commercially insured patients and $149 per month for self-pay at the lowest dose. Lilly USA President Ilya Yuffa stressed that approval is only the beginning, since coverage, access, and cost often determine whether people can start treatment and stay on it.
The approval was supported by the phase 3 ATTAIN program. In ATTAIN-1, adults on the highest dose who completed treatment lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds on placebo. At the same time, early reaction has included an important note of caution. Albert pointed out that while Foundayo improved cardiovascular risk markers, it does not yet have cardiovascular outcomes data.
The larger story is that Lilly is betting convenience, access, and affordability can bring more people into treatment. If that happens, Foundayo will do more than intensify competition with Novo Nordisk. It could help make oral obesity treatment more practical for everyday use.
Update: Novo Nordisk Pushes Back on Oral GLP-1 Comparisons
Novo Nordisk is now pushing back directly on comparisons between Wegovy pill and Lilly’s newly approved Foundayo. In materials released ahead of Obesity Medicine Association 2026, Novo said an indirect comparison of phase 3 trial data showed greater average weight loss with oral semaglutide 25 mg than with orforglipron 36 mg, while also reporting lower odds of discontinuation due to adverse events. The company also cited a separate patient preference study in which most respondents favored a treatment profile similar to oral semaglutide. At the same time, Novo and outside coverage both note that these findings come from indirect and simulated comparisons, not a head-to-head trial, so they add competitive context but do not settle the question.
Update: Foundayo Now Available in the U.S.
Lilly announced on April 9 that Foundayo is now available in the United States. According to the company, patients can access it through LillyDirect and telehealth providers, with retail pharmacy availability beginning nationwide the same day.
Sources
Eli Lilly Press Release
Fierce Pharma Coverage
LinkedIn Post - Michael Albert, MD
LinkedIn Post - Ilya Yuffa
LinkedIn Post - Robert Gabbay, MD, PhD
Sources for Update
Novo Nordisk Press Release
Fierce Pharma Coverage
Source for Availability Update
